Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies

Inclusion Criteria: * Aged ≥ 18 years, regardless of gender. * Expected survival time ≥ 3 months. * ECOG performance status score of 0-1. * Confirmed diagnosis of relapsed/refractory CD7-positive hematolymphoid malignancies at screening. * Coagulation function, liver and kidney function, and cardiopulmonary function meeting the requirements. * Ability to understand the trial and signed informed consent form. Exclusion Criteria: * A history of malignant tumors other than hematolymphoid malignancies within 5 years prior to screening, excluding carcinoma in situ. * Positive results for virological tests or syphilis. * Severe cardiac diseases. * Unstable systemic diseases as determined by the investigator. * Active or uncontrolled infections requiring systemic treatment within 7 days prior to screening, excluding mild urinary and reproductive system infections and upper respiratory tract infections. * Pregnant or lactating women; female subjects planning to become pregnant within 2 years after cell infusion; or male subjects whose partners plan to become pregnant within 2 years after the subject's cell infusion. * Subjects receiving systemic corticosteroid therapy within 7 days prior to screening, or those judged by the investigator to require long-term systemic corticosteroid therapy during the trial period, excluding inhaled or topical administration. * Participation in other clinical studies within 1 month prior to screening. * Evidence of central nervous system (CNS) involvement at screening, such as detection of tumor cells in cerebrospinal fluid (CSF) or imaging findings suggestive of CNS infiltration. * Patients requiring long-term use of immunosuppressants as determined by the investigator at screening. * A history of epilepsy or other central nervous system diseases. * Patients with primary immunodeficiency diseases. * Other circumstances deemed inappropriate for enrollment by the investigator.